Reports Q2 revenue $1.87B, consensus $1.82B. “Our performance and execution in Q2 allowed us to deliver another strong quarter that was above our expectations, despite ongoing challenges in the macroenvironment,” said Bryan Hanson, Chairman, President and CEO of Zimmer Biomet. “We are raising our financial guidance for the rest of 2023 based on our confidence in our business performance, the strength of our innovation pipeline and the Zimmer Biomet team’s ability to deliver for our key stakeholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ZBH:
- Zimmer Biomet Announces Second Quarter 2023 Financial Results
- ZBH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Zimmer Biomet price target raised to $153 from $147 at Truist
- Zimmer Biomet target raised, added to ‘Tactical Outperform’ list at Evercore ISI
- Early notable gainers among liquid option names on June 14th